The QualityStocks Daily Friday, July 19th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (AGHC) +56.91%

StockMarketWatch (MTP) +43.08%

SmallCapRelations (ORHB) +27.78%

The QualityStocks Daily Stock List

Table Trac, Inc. (TBTC)

NetworkNewsWire, Momentous News, Stockwatch, Simply Wall St, Last10k, CapitalCube, Wallet Investor, TradingView, Stockopedia, OTC Markets, Stockhouse, PR Newswire, Market Screener, and Stockhouse reported beforehand on Table Trac, Inc. (TBTC), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Table Trac, Inc. is a developer and provider of casino information and management systems, which automate and monitor the operations of casinos. It has systems installed in North, South, and Central America, and also the Caribbean. The Company’s mission is to design, build, sell and maintain the most innovative complete solution casino management system. OTCQB-listed and established in 1995, Table Trac has its head office in Minnetonka, Minnesota.

Fundamentally, the Company develops and sells a suite of casino management products from its patented Table Trac table games management system. This system automates and monitors the operations of casino table games to CasinoTrac, which is a complete casino management system with functionality modules for guest rewards and loyalty club, marketing analysis, guest service, promotions administration/management, vault/cage management, and audit/accounting.

Table Trac has launched a number of revenue-generating products for casinos since 2005. These include KioskTrac, Progressive, and Text-to-Win. The design of KioskTrac is to reward players and create player loyalty and increased casino visitation via interactive games and promotions. Progressive is an inventive way to create loyalty and increase carded play at the table games. The iProgressive is a wide-area and local area progressive and digital signage package. It promotes the games and the property right at the tables. With Text-to-Win, players can now send SMS text messages to receive offers and promotions.

Last month, Table Trac announced it will provide its Table Games Management System for the Island Resorts and Casino located in Harris, Michigan. It will provide the Island Resort and Casino with a total set of table games management products that assists casinos in boosting player revenues and creating player loyalty, which are included standard with every Table Trac Table Games Management System. Table Trac's casino management system is in greater than 150 casinos in 12 countries. It is multi-lingual, multi-currency, as well as multi-tax reporting.

Table Trac's Chief Executive Officer, Mr. Chad Hoehne, stated, "We are excited to enter the Michigan market and to be partnered with Island Resort. Table Trac has entered a number of new gaming jurisdictions over the past few years, and I am gratified to see the global appreciation and growth of both our products."

Tokyo, Japan based BroadBand Security, Inc. (4398.T) engages in the business of information technology, security management, and consulting services. It has signed an exclusivity contract with Table Trac to integrate the CasinoTrac Casino Management System (CMS) to the Japanese Gaming market where legalized gambling was officially approved in September 2018. The project, led by BroadBand Security, will comprise a working team of companies to provide a comprehensive resort and casino management package for the "Japan Integrated Resorts Combined Management System Project."

Table Trac, Inc. (TBTC), closed Friday's trading session at $3.20, up 5.9603%, on 600 volume with 3 trades. The average volume for the last 3 months is 1,614 and the stock's 52-week low/high is $1.85000002/$3.5999999.

chart

American Hotel Income Properties REIT LP (AHOTF)

Stock Target Advisor, Marketbeat, Wallet Investor, Morningstar, Stockhouse, Stockwatch, Wallmine, and OTC Markets reported previously on American Hotel Income Properties REIT LP (AHOTF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American Hotel Income Properties REIT LP, or AHIP, is a limited partnership established to invest in hotel real estate properties located in the United States. AHIP hotels operate under brands affiliated with Marriott, Hilton, IHG, Wyndham and Choice Hotels via license agreements. AHIP’s long-term objectives are to build on its proven track record of successful investment, deliver reliable and consistent U.S. dollar denominated distributions to unitholders, and generate value through the continued growth of its varied hotel portfolio. AHIP is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQX.

AHIP is led by an experienced management team consisting of proven hotel industry leaders, including award-winning entrepreneurs and executives. AHIP currently has 112 hotels. The Company engages in growing its portfolio of premium branded, select-service hotels in larger secondary markets, which have diverse and stable demand.

The Company looks for properties distinguished by stabilized in-place income; and an all-in trailing capitalization rate greater than 8 percent; and also acquisition cost below replacement cost; and strong demand generators. In addition, AHIP looks for properties with limited new supply; that complement existing premium branded, Select-Service hotels; and targeted geographic diversification within the U.S. Consistent with its acquisition strategy, all properties are strategically situated within or close to larger population centers, transportation corridors, as well as demand generators.

This week, AHIP announced that it recently completed roughly US$5.0 million of renovations at three hotels. These are the Fairfield Inn & Suites by Marriott Jacksonville ( Florida ); the Homewood Suites by Hilton Allentown ( Pennsylvania ); and the Homewood Suites by Hilton Bethlehem ( Pennsylvania ). In total, ten hotels will be renovated during this year, including the three hotels already completed.

Mr. John O'Neill , AHIP Chief Executive Officer, said, "We are very pleased to have these renovations completed on time and on budget, with no further disruption to our guests or business levels at these properties. These hotels now offer the latest designs and guest comforts, enhancing our guest experience and best positioning these properties in their respective markets."

AHIP intends to release its financial results, for the quarter ended June 30, 2019, after market close on Thursday, August 8 , 2019. Interested parties are invited to participate in its Q2 2019 results conference call, taking place later that same day at 5:30 p.m. Eastern Time/2:30 p.m. Pacific Time. During the call, AHIP executives will discuss the Company's financial results and answer questions from analysts.

American Hotel Income Properties REIT LP (AHOTF), closed Friday's trading session at $5.22, up 1.1348%, on 43,904 volume with 51 trades. The average volume for the last 3 months is 15,538 and the stock's 52-week low/high is $4.34070014/$7.21999979.

chart

Hut 8 Mining Corp. (HUTMF)

CoinNews Telegraph, Invest Tribune, Stockwatch, Market Screener, Stockhouse, Wallet Investor, 4-Traders, Investorx, YCharts, InvestorsHub, Midas Letter, Trading View, MarketWatch, Seeking Alpha, Morningstar, Investor Ideas, Small Cap Power, OTC Markets, and Cryptocredits reported previously on Hut 8 Mining Corp. (HUTMF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Hut 8 Mining Corp. is one of the world's largest publicly traded cryptocurrency mining companies by operating capacity and market capitalization. It has industrial scale bitcoin mining operations in Canada. The Company provides investors with direct exposure to bitcoin, without the technical complexity or constraints of buying the underlying cryptocurrency. Therefore, investors avoid the need to create online wallets, wire money offshore, and safely store their bitcoin. Hut 8 Mining’s registered office is in Vancouver, British Columbia.

Hut 8 Mining has an exclusive North American partnership with the Bitfury Group Limited, inclusive of Bitfury Holding BV, (Bitfury), one of the world's top full-service hardware and software blockchain technology companies. The Bitfury Group’s expertise ensures successful, secure, and cost-effective connectivity to the blockchain. Bitfury provides turn-key service to install, service, as well as maintain BlockBox datacenters.

Hut 8 Mining has an exclusive option for the future acquisition and development of datacenters and an extensive and proprietary mix of hardware, software, installation and operational services in North America. Concerning secured, low cost electricity, it is operating 95.2 MW in Drumheller and Medicine Hat, Alberta, with access to more power in Canada.

In Drumheller, Alberta, 29 BlockBox datacenters are operating at a maximum capacity of 32.5 MW producing 280 PH/s at full load. In Medicine Hat, Alberta, 56 BlockBox datacenters are operating at a maximum capacity of 62.7 MW and 504 PH/s at full load.

Last week, Hut 8 Mining announced that for Q2 it mined 2,816 bitcoin and Retained Bitcoin of 3,250, both the highest quarterly amount in the Company's history. In addition, the Company announced that it will release its Q2 2019 financial results before market open on Monday, August 19, 2019.

Mr. Andrew Kiguel, Hut 8 Mining’s Chief Executive Officer, said, "Hut 8's strategy to only mine and retain bitcoin, after paying its expenses, has resulted in substantial value creation for investors in the second quarter of 2019 In Q2-2019, we experienced lower electricity prices than the prior quarter and a much improved bitcoin price."

Hut 8 Mining Corp. (HUTMF), closed Friday's trading session at $1.7961, up 4.9185%, on 23,848 volume with 33 trades. The average volume for the last 3 months is 35,948 and the stock's 52-week low/high is $0.599099993/$2.8499999.

chart

One World Pharma, Inc. (OWPC)

PennyStockBase, Stocks News Feed, Simply Wall St, Daily Marijuana Observer, NewMediaWire, PR Newswire, Street Insider, Dividend Investor, Investors Hangout, Oil and Gas 360, TradingView, Seeking Alpha, Stockwatch, Stockopedia, GlobeNewswire, and InvestorsHub reported previously on One World Pharma, Inc. (OWPC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

One World Pharma, Inc. is the U.S. parent company of One World Pharma S.A.S, which is a fully licensed cannabis and hemp producer with offices and operations in Bogota and Popayan, Colombia. The Company’s intention is to supply the highest quality cannabis and hemp derivatives in crude oil, distillate and isolate forms with industrial scale production to serve worldwide cannabis demand. One World Pharma products will be produced and tested to GMP and ISO standards. The Company lists on the OTC Markets. It has its U.S. office in Las Vegas, Nevada.

In 2018, One World Pharma planted its first crop of cannabis at its cultivation site in Popayan, Colombia, for research purposes. The Company expects to commence harvesting commercially in Q4 of this year. One World Pharma uses their wide-ranging knowledge and research of the cannabis plant to cultivate specific strains from around the world - with 25 registered strains at ICA (Instituto Colombiano Agropecuario) and dozens more awaiting approval.

In essence, One World Pharma is a large-scale producer of high-quality cannabis and hemp products for the medical and commercial markets. The Company has more cultivation facilities under contract in addition to its Popayan, Colombia (135KM south of Cali) facility. One World Pharma has been granted four licenses for the cultivation of Non-Psychoactive (Low) THC, Psychoactive (High) THC, and the manufacture of cannabis derivatives and seeds.

This past April, One World Pharma announced it was granted permission by ICA to start cultivating 13 proprietary high THC cannabis strains and 2 high CBD strains. The approval greatly speeds up the Company’s efforts as one of the first cultivators of scale in the highly desirable Colombian production environment. One World Pharma’s next step will be to put these strains through characterization tests to confirm their genetic attributes, in particular local environments. Upon successful characterization tests, the Company will register these cannabis strains and genetics and be in a position to cultivate for commercial purposes. It anticipates getting permission to put additional strains through this process during 2019.

In May, One World Pharma announced that it entered into its first seed sale agreement in Colombia with Mr. Kevin Steven Ocampo Prieto of Bogota. Via this long term, evergreen agreement, the Company agreed to provide Mr. Prieto with seeds of its non-psychoactive cannabis strains that are in the registration procedure for the national register of commercial cultivars of the ICA.

One World Pharma, Inc. (OWPC), closed Friday's trading session at $3.87, up 29.00%, on 235 volume with 7 trades. The average volume for the last 3 months is 198 and the stock's 52-week low/high is $0.400000005/$4.50.

chart

Pulse Seismic, Inc. (PLSDF)

Micro Small Cap, CapitalCube, TMX Money, Wallet Investor, TeleTrader, TradingView, Market Screener, StreetWise Reports, Stockhouse, Stockwatch, EnergyNow.ca, and GlobeNewswire reported previously on Pulse Seismic, Inc. (PLSDF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Pulse Seismic, Inc. is a market leader in the acquisition, marketing, and licensing of 2D and 3D seismic data to the western Canadian energy sector. The Company owns the largest licensable seismic data library in Canada, presently comprising roughly 65,310 square kilometers of 3D seismic and 829,207 kilometers of 2D seismic. Pulse Seismic’s shares trade on the OTC Markets Group’s OTCQX. The Company is based in Calgary, Alberta.

Pulse Seismic’s library extensively covers the Western Canada Sedimentary Basin where the majority of Canada’s oil and natural gas exploration and development takes place. The Company’s library covers important areas in Alberta, Northeast British Columbia, as well as Saskatchewan. It includes portions of the Northwest Territories, the Yukon, Manitoba, and Montana.

Pulse Seismic is continually expanding its data library. It does so through purchasing data from different sources, including seismic acquisition companies and exploration companies, and by adding new data acquired via participation surveys.

The Company’s data library is the second-largest that is freely available in the industry. The majority of Pulse’s data sets cover the full range of prospective geological zones, unlike some data sets that concentrate on particular targets at specific depths. The Company’s team approach to the data licensing business enables it to provide clients with quality inspections in under 24 hours.

The price of Pulse Seismic’s data sets is determined by its location, its vintage, the data quality, its fold (high or low) and the original acquisition costs. Pulse’s focus is to remain price-competitive with other seismic data providers.

Regarding 2D Seismic Data Sets, the Company provides premier 2D seismic data in the Western Canada Sedimentary Basin. Its data sets encompass the complete range of prospective geological zones. This allows a client to examine a broad range of targets or prospective zones at varying depth. Pertaining to 3D Seismic Data Sets, Pulse Seismic shoots and acquires multi-zone 3D. Its 3D data is well-suited for shallow through deep exploration.

Last month, Pulse Seismic announced it completed a $7.0 million sale of 3D seismic data. The sale comprises a transaction-based obligation along with a new licence for additional 3D data.

Mr. Neal Coleman, Pulse Seismic President and Chief Executive Officer, said, “We are extremely pleased by this transaction, which clearly supports the business case for Pulse’s January 2019 purchase of Seitel Canada Ltd. Transaction-based sales have become a significant component of our data library licensing business in recent years, and we continue to believe that our acquisition will help grow and potentially smooth Pulse’s annual revenues over time.”

Yesterday, Pulse Seismic reported its financial and operating results for the three and six months ended June 30, 2019. Data library sales revenue was $10.6 million for the three months ended June 30, 2019, versus $1.9 million for the three months ended June 30, 2018. Data library sales revenue was $15.9 million for the six months ended June 30, 2019, versus $4.2 million for the six months ended June 30, 2018.

Net earnings for the three months ended June 30, 2019, were $2.9 million ($0.05 per share basic and diluted) versus a net loss of $1.0 million ($0.02 per share basic and diluted) for the three months ended June 30, 2018. Net earnings for the six months ended June 30, 2019, were $209,000 ($0.00 per share basic and diluted) versus a net loss of $1.7 million ($0.03 per share basic and diluted) for the six months ended June 30, 2018.

Pulse Seismic, Inc. (PLSDF), closed Friday's trading session at $1.66, up 1.5291%, on 3,400 volume with 13 trades. The average volume for the last 3 months is 2,312 and the stock's 52-week low/high is $0.995199978/$1.98000001.

chart

Rokk3r, Inc. (ROKK)

Street Insider, OTC Markets, Market Screener, Stockwatch, Dividend Investor, Wallet Investor, TradingView, Stockhouse, Simply Wall St, Last10k, PR Newswire, and GlobeNewswire reported earlier on Rokk3r, Inc. (ROKK), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Rokk3r, Inc. is an international idea-to-exit company builder and consulting services enterprise. The Company takes advantage of exponential technologies to generate value. Rokk3r provides a set of services. This set is a hybrid network of human and machine intelligence systems, seeking to enable early stage start-up technology companies and existing businesses to develop new products and businesses in a frictionless, accelerated and complete manner.

Rokk3r lists on the OTC Markets. The Company formerly went by the name Eight Dragons Company. It changed its corporate name to Rokk3r, Inc. in March of 2018. Rokk3r is based in Miami, Florida.

The design of the Company’s services are to leverage exponential technologies to quickly accelerate and shape industries. These exponential technologies include artificial intelligence (AI); augmented and virtual reality (AR, VR); blockchain (decentralized ledger technologies); data science; digital biology and biotech; machine learning; nanotech; robotics, and sensors.

Rokk3r helps companies augment and transform exponentially. The Company provides business diagnosis to strategy design, execution and funding. Its ecosystem approach lessens friction and streamlines execution through taking advantage of talent, shared services, experience, as well as networks.

The Company provides its services with the purpose of allowing its clients to concentrate on the creative facets of building a business or creating new products. Rokk3r relieves clients from the burden of developing an operational and development infrastructure. Via the Company’s methodology and ecosystem, Rokk3r seeks to make new business opportunities become highly investable assets for venture fund and other investment funds.

Rokk3r recently acquired Bullfrog Ventures. Bullfrog was founded in 2016. Its mission is to speed up the transition of insurance solutions to be more predictive and preventive, decreasing material damages and improving people's lives. Since its inception, Bullfrog has played a key role in the development of manifold enterprise-level firms in North and South America. This includes that of multinationals, such as SURA, QBE and Global Excel Management.

In June, Pallco, a peer-to-peer network that connects users in need of storage space with idle warehouse space, announced it officially launched, with clients such as Advanced Appealing Technologies and A4México onboard. Pallco works to empower entrepreneurs and lessors of excess commercial spaces with a “warehousing-as-a-service” platform. This platform enables users to rent or list warehouse space on a flexible, as-needed basis. With plans to scale to South America, Pallco will work with Rokk3r to create and execute upon a roadmap for expansion.

Also in June, Rokk3r announced its appointment of Ms. Andrea Arnau as Chief Marketing Officer. In this role, Ms. Arnau will lead Rokk3r’s initiatives to build industry awareness as it utilizes disruptive technologies for growth building exponential organizations. Ms. Arnau joined Rokk3r in 2015 as an experienced digital marketing executive and serial entrepreneur, having served as Co-Founder of three digital agencies, Tribal Colombia, Chef Company, and Tribal US Hispanic.

Rokk3r, Inc. (ROKK), closed Friday's trading session at $1.00, even for the day, on 150 volume with 1 trade. The average volume for the last 3 months is 3,043 and the stock's 52-week low/high is $0.497500002/$4.00.

chart

Sun BioPharma, Inc. (SNBP)

PipelineReview, Street Insider, GlobeNewswire, The Stock Market Watch, Market Screener, Seeking Alpha, Stockhouse, Dividend Investor, Wallet Investor, Last10k, Stockopedia, Whale Wisdom, Simply Wall St, Morningstar, Investing.com, 4-Traders, and TradingView reported previously on Sun BioPharma, Inc. (SNBP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A clinical stage biopharmaceutical company, Sun BioPharma, Inc. is developing disruptive therapeutics for the treatment of pancreatic diseases. Its development programs target diseases of the pancreas, including pancreatic cancer and pancreatitis. The Company’s initial product candidate is SBP-101 for the treatment of patients with pancreatic cancer. Sun BioPharma’s shares trade on the OTC Markets Group’s OTCQB. The Company is headquartered in Waconia, Minnesota.

Sun BioPharma, Inc. and its wholly-owned subsidiary, Sun BioPharma Pty. Ltd., is a next-generation biopharmaceutical company. The Company has scientific collaborations with pancreatic disease experts at Honor Health in Scottsdale, Arizona; Cedars Sinai Medical Center in Los Angeles, California; the University of Minnesota; Mayo Clinic Scottsdale; the Austin Health Cancer Trials Centre; as well as the Ashford Cancer Centre in Adelaide, Australia.

Sun BioPharma has SBP-101 and SBP-102 in drug development. SBP-101 is a proprietary polyamine licensed by the Company from the University of Florida in 2011. Sun BioPharma’s intention is to develop SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. A first-line dose-escalation study of SBP-101 in combination with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic cancer is presently enrolling patients. Currently, SBP-102 is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis.

Regarding the Front-Line Combination PDA Study, Sun BioPharma’s current trial, a Phase 1a/1b combination of SBP-101 to be administered with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA), completed cohort 2 enrollment and expected the Data Safety Monitoring Board to meet before the end of May 2019 to review interim results of the cohort.

In addition, the Company added a fifth clinical site, the John Flynn Private Hospital in Tugun, Queensland Australia at the end of Q1. In the Phase 1a portion of the study treatment of up to 18 PDA patients, it was planned in three cohorts to ascertain a recommended dose of SBP-101 to be given in combination with standard treatment. The Phase 1b portion will be an expansion at the recommended dose of SBP-101. It will guide SBP-101’s subsequent development for patients with PDA.

Sun BioPharma, Inc. (SNBP), closed Friday's trading session at $3.50, off by 6.6667%, on 100 volume with 1 trade. The average volume for the last 3 months is 477 and the stock's 52-week low/high is $2.00/$5.00.

chart

Beyond Commerce, Inc. (BYOC)

Zacks, OTC Markets, Penny Stock Tweets, Stockhouse, InvestorsHub, YCharts, Street Insider, Market Screener, Wallet Investor, Simply Wall St, Financial Content, MarketWatch, Investors Hangout, Barchart, The Street, Tip Ranks, 4-Traders, GuruFocus, Stockopedia, OTC.Watch, TradingView, Morningstar, Insider Financial, and Stockinvest reported earlier on Beyond Commerce, Inc. (BYOC), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Beyond Commerce, Inc. is a planned provider of B2B (Business to Business) internet marketing analytics, technologies, and related services. The Company’s planned objective is to develop, acquire, and deploy disruptive strategic software technology that will build on organic growth potential. Additionally, its planned goal is to exploit cross-selling opportunities. Beyond Commerce is based in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company operates as a holding enterprise that focuses on “big data” companies in the global B2B Internet Marketing Analytics/Technology and Services space. Beyond Commerce plans to provide a cohesive digital product and services platform. This is to provide clients with a single point of contact for their big data, marketing and related sales initiatives. The Company’s emphasis is to develop, acquire, and also deploy disruptive strategic software technology and market-changing business models through acquisition or organic growth.

In August of 2018, Beyond Commerce announced that it was added to the LD Micro Index effective August 1, 2018. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said at that time, "This is an exciting time for us as we continue to execute on business milestones which are translating into additional exposure in the capital markets and building on our goals for corporate transparency and credibility with stakeholders. LD Micro has championed the microcap space and I am proud that we have been included in their index and to be recognized with other successful peers in the microcap space."

Yesterday, Beyond Commerce announced that it signed a definitive business combination agreement with PathUX, LLC. Beyond Commerce Chairman and Chief Executive Officer, Mr. George Pursglove, said, "PathUX provides Cloud based marketing automation software and will make a great addition to our future vision, has recurring revenues and a great team. We look forward to our future growth plans together. We expect the provisions of the agreement to be implemented in the second quarter of 2019.”

Beyond Commerce, Inc. (BYOC), closed Friday's trading session at $0.0026, up 48.0638%, on 20,327,488 volume with 127 trades. The average volume for the last 3 months is 4,400,991 and the stock's 52-week low/high is $0.0017/$0.100000001.

chart

Nemaska Lithium, Inc. (NMKEF)

Investing News, Streetwise Reports, Uptick News Wire, InvestorIntel, OTC Markets, Street Insider, Private Capital Journal, Metals News, Mining and Energy, Insider Financial, Stockhouse, Capital Equity Review, InvestorsHub, YCharts, and Junior Mining Network reported previously on Nemaska Lithium, Inc. (NMKEF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

A developing chemical company, Nemaska Lithium, Inc.’s activities will be vertically integrated. This is from spodumene mining to the commercialization of high-purity lithium hydroxide and lithium carbonate. These lithium salts are chiefly for the lithium-ion battery market. Nemaska Lithium will be operating the Whabouchi mine in Quebec, Canada. The Whabouchi mine is one of the richest lithium spodumene deposits globally - in volume and grade. Nemaska Lithium is based in Quebec City, Quebec.

The spodumene concentrate produced at the Whabouchi mine will undergo processing at the Shawinigan plant employing an inventive membrane electrolysis process for which Nemaska Lithium holds several patents. The Company has received a notice of allowance of a main patent application on its proprietary process to produce lithium hydroxide and lithium carbonate. It is pursuing patent protection on this process in numerous worldwide jurisdictions.

The Whabouchi Property comprises one block totaling 33 claims covering an area of 1,761.9 ha. Nemaska Lithium 100 percent owns the claims. The Feasibility Study (FS) outlines a combined open pit and underground mine. The Company states that the Nemaska Whabouchi spodumene deposit in the Eeyou Istchee/James Bay Region of Quebec, near the Cree community of Nemaska, should have an initial lithium mine life of 26 years.

Last week, Nemaska Lithium announced that construction work at the Whabouchi mine will resume on Tuesday, February 5, 2019. Mine construction activities were put on hold on Thursday, January 31, 2019 following a fire in the cafeteria of the Nemiscau workcamp, a facility owned and operated by an outside contractor that is located about 15 km away from the Nemaska Lithium mine site.

Nemaska Lithium located an alternate cafeteria facility that is roughly 1 km from the existing lodging facility, which will be opened to accommodate Nemaksa Lithium’s employees until mid-March. This is when the Whabouchi mine site workcamp now under construction will be opened.

Nemaska Lithium, Inc. (NMKEF), closed Friday's trading session at $0.2385, up 44.5455%, on 621,291 volume with 160 trades. The average volume for the last 3 months is 94,982 and the stock's 52-week low/high is $0.159999996/$0.720000028.

chart

Vegalab, Inc. (VEGL)

OTC Markets, GuruFocus, Simply Wall St, YCharts, Investors Hangout, Stockwatch, Capital Cube, InvestorsHub, TradingView, Business Insider, PennyStockHub, Wallet Investor, Barchart, MarketWatch, InvestingNewsAlerts, Stockhouse, and Stockopedia reported earlier on Vegalab, Inc. (VEGL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Vegalab, Inc. is the exclusive distributor in North and South America of a line of all-natural, biologically derived pesticides, fertilizers, and specialty agricultural products. Its products support a healthy soil biome. Additionally, they are cost competitive with synthetic chemicals that do just the opposite. The Company’s products include Biocontrol Agents, Insecticides, Fungicides, Soil Inoculants, and Fertilizers. Vegalab has its corporate office in North Palm Beach, Florida.

Vegalab operates in two segments of the food industry. These are the Agronomy Business and the Packing Business. The Agronomy Business involves the manufacture and distribution of all-natural crop protection, crop health, and soil enhancement products. The Packing Business operates a citrus packing facility.

All of the Company’s oil-based products go through a process of micronization. This gives the oils the ability to cover a larger surface area and enables deeper penetration into the crevices of plants, insects, and pathogens. The minute pores and filaments in the plant absorb Vegalab’s products faster versus conventional oils.

Vegalab’s pesticides are highly effective against targeted organisms, non-toxic to beneficial organisms, and safe for the environment. Every Vegalab product strives to enhance productivity and lessen waste.

In October 2017, Vegalab purchased M&G Packing. The facility consists of approximately 11 acres of real property and 30,000 sq. ft. of buildings. In March 2018, Vegalab announced that it completed its acquisition of The Agronomy Group, LLC effective as of February 1, 2018. The Agronomy Group (TAG) is located in Tulare County, California. It is a producer and distributor of environmentally friendly agrochemicals and also distributes other products.

In November 2018, Vegalab announced the acquisition, subject to a lease option agreement that runs through November 1, 2019, of a major fruit packing facility in Lindsay, California. The facility (on 9.4 acres in California’s San Joaquin Valley) comprises greater than 260,000 square feet of working space. This includes three packing lines, roughly 32,000 square feet of cold storage, 12 de-greening rooms, and a 6 bay shipping area.

This facility will significantly increase Vegalab’s present capacity to process and pack fruit. Vegalab’s management team believes the acquisition will boost the Company’s overall fruit processing capacity to more than US $150 million annually. The current capacity at the facility is about 200 bins per hour.

This month, Vegalab announced it will start selling its products via all three locations of Pratum Co-op, a well-known and fast growing agricultural retailer based in the diverse growing region of the Willamette Valley in Oregon. Pratum Co-op is a supplier of fertilizer, crop protection and petroleum products. Pratum has three state of the art locations to serve its members who are prominent growers of grass seeds, blueberries, hazelnuts, grapes, hay, carrot seed and more.

Vegalab, Inc. (VEGL), closed Friday's trading session at $1.00, up 40.8451%, on 500 volume with 1 trade. The average volume for the last 3 months is 719 and the stock's 52-week low/high is $0.009999999/$3.75.

chart

International Frontier Resources Corporation (IFRTF)

Connecting Investor, YCharts, Wallet Investor, GuruFocus, 4-Traders, MarketWatch, Stockhouse, Marketwired, Otc.Watch, Investment Pitch, Investors Hub, Investing News, Market Screener, and Emerging Growth reported earlier on International Frontier Resources Corporation (IFRTF),  and today we report on the Company, here at the QualityStocks Daily Newsletter.

International Frontier Resources Corporation has a demonstrated track record of advancing oil and gas projects. The OTCQB-listed Company, by way of its Mexican subsidiary, Petro Frontera S.A.P.I de CV and strategic joint ventures (JVs) is advancing the development of petroleum and natural gas assets in Mexico.  International Frontier Resources is based in Calgary, Alberta.

International Frontier Resources (IFR) also has projects in the U.S. and Canada. This includes the State of Montana and the Northwest Territories. IFR created a JV company in 2015 - Tonalli Energia - together with Grupo Idesa, one of Mexico’s largest petrochemical companies.  Grupo Idesa is a well-established Mexican petrochemical company.

Block 24 Tecolutla establishes IFR’s Mexican JV as one of the first operators’ in Mexico. In addition, it provides important insights into future rounds. Tecolutla is a very underdeveloped mature field with considerable upside potential.  The Tecolutla Block is in the Tampico-Misantla Basin within the State of Veracruz.

The Tecolutla Field is 7.2 square kilometers. It contains an oil reservoir at 2,340 meters or around 7,700 feet. The Tecolutla Block is a 60-80 m gross pay carbonate reservoir on a structural high with proven oil production. 

Tonalli has submitted the regulatory applications and documentation that will allow IFR to go ahead with the drilling permit and operations at Tecolutla. The expectation is that the existing wells at Tecolutla will exceed historic production numbers and peak initial production (IP) rates with the arrival of new recovering techniques, technology, and expertise to be undertaken by Tonalli.

This past November, International Frontier Resources Corporation (IFR) announced that Tonalli Energia, IFR’s JV with Mexican petrochemical leader Grupo IDESA, spudded the first conventional horizontal well, (TEC-11), at its onshore Tecolutla block. TEC-11 is the initial horizontal well in a potential multi-well plan to develop the northern extension of the Tecolutla field that has been identified on Tonalli’s interpretation of the 3D seismic.

Moreover, in December, IFR announced that Tonalli Energia reached total depth at its first conventional horizontal well, (TEC-11), on its onshore Tecolutla block. The TEC-11 field development horizontal well was drilled to a depth of 3283 meters (m) Measured Depth (MD). A total of roughly 670m of measured length of Cretaceous limestone was drilled before the total depth was reached. Oil shows were encountered during drilling.

Furthermore, Tonalli received its first payment from PEMEX for oil shipped from its Tecolutla field. Tonalli’s TEC-10 producing well averaged 156 barrels of oil per day in October and November at an approximate average crude sales price of USD$64.73 per barrel.

International Frontier Resources Corporation (IFRTF), closed Friday's trading session at $0.0356, up 38.5214%, on 91,200 volume with 20 trades. The average volume for the last 3 months is 10,964 and the stock's 52-week low/high is $0.025599999/$0.163800001.

chart

Alltemp, Inc. (LTMP)

MissionIR, Stock Communications Group, Dividend Investor, 4-Traders, InvestorsHub, GuruFocus, The Street, Investors Hangout, Barchart, StockInvest, MarketWatch, Stockhouse, Morningstar, Wallet Investor, Market Screener, and Capital Cube reported earlier on Alltemp, Inc. (LTMP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Alltemp, Inc. is a developer of proprietary, environmentally-friendly, refrigerant technologies. The Company has developed a proprietary refrigerant technology, called alltemp®. This is a proven replacement for many global refrigerants that have adversely affected the worldwide environment.  Alltemp is based in Westlake Village, California.

alltemp®’s refrigerants are for the commercial and residential markets. alltemp® is the Company’s solution for the replacement of R-407c, R-134a, R-404a, and HCFC-22, known as R-22, but which is quickly being phased out in all developed nations because of environmental concerns over its strong effect on the depletion of the Earth's ozone layer.   

alltemp® refrigerants have broad applications. These range from Heating Ventilation and Air Conditioning (HVAC), to refrigeration and foam insulation, to industrial solvents. alltemp® solutions provide a sustainable, eco-friendly, true drop-in refrigerant. It meets the Montreal/Kyoto Protocols and EPA  (Environmental Protection Agency) standards with the lowest Global Warming Potential for any non-flammable HFC. alltemp®  yields a 27 percent average decrease in kWh,  without loss in capacity.

Alltemp successfully completed two years of early adopter testing of its alltemp® refrigerant at several Fortune 100 companies' facilities for its Montreal and Kyoto Protocol compliant refrigerant. Furthermore, test results revealed that alltemp® yielded significant average savings in energy consumption. This is while maintaining capacity. 

Alltemp announced in January 2018 that it released a new refrigerant alternative for R-404A applications called alltemp® 4. This is a drop-in refrigerant. R-404A has one of the highest GWPs (Global Warming Potential) of any HFC refrigerants. It is quickly being phased out in the European Union (EU) and other developed countries.

Alltemp announced in March 2018 that flashpoint chamber testing conducted by DEKRA Insight confirmed that alltemp® refrigerant has zero flammability. A minimum of 20 different chamber tests in the liquid phase and 20 vapor phase tests, with temperatures as high as 60º C = 140º F, revealed zero flammability and no ignition with alltemp® refrigerant.

Alltemp has its R-410A replacement refrigerant, designated alltemp® H. Like the Company’s other refrigerants, alltemp® H is engineered to use the same anti-corrosive and non-flammable alltemp® core technology that provides major energy efficiencies and meets ASHRAE A1 safety classification standards.

R-410A was designed to replace R-22, which has a substantial environmental impact and Ozone Depletion Potential (ODP). The lower the GWP value, the better the refrigerant is for the environment. R-410A has a Global Warming Potential (GWP) rating of 2,088. Its predecessor R-22 has a GWP rating of 1700.

Alltemp, Inc. (LTMP), closed Friday's trading session at $0.065, up 18.1818%, on 382,630 volume with 17 trades. The average volume for the last 3 months is 74,443 and the stock's 52-week low/high is $0.029999999/$0.172499999.

chart

AEON Global Health Corp. (AGHC)

Amigo Bulls, Stock Target Advisor, Stockopedia, Investors Hangout, Penny Stock Hub, Stockwatch, Simply Wall St, Zacks, Stockhouse, InvestorsHub, YCharts, TradingView, The Street, Stockflare, and Dividend Investor reported on AEON Global Health Corp. (AGHC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

AEON Global Health Corp., together with its subsidiaries, provides a variety of clinical laboratory testing services in the United States. The Company provides diagnostic services in Cancer Genomics, Toxicology, Pharmacogenomics, as well as Health Technology Applications. AEON formerly went by the name Authentidate Holding Corp. It changed its name to AEON Global Health Corp. in January 2018. OTCQB-listed, AEON Global Health has its corporate office in Gainesville, Georgia.

The Company is the fastest growing clinical lab and healthcare services organization in the United States. It is first in healthcare technology research and development (R&D) where its proprietary methodologies provide expedited and highly accurate urine and oral fluid (saliva) test results. AEON’s chief business focus is providing a “personalized medicine” approach to laboratory testing services. This is to provide customers with actionable medical information.

AEON is an innovator in the genomic testing area. The Company has an extensive menu of genetic tests and a pipeline of additional molecular-based tests in development. It provides post contract customer support services. The design of AEON’s Telehealth Solutions is to improve outcomes and reduce hospital readmission through helping clinicians closely monitor patients with chronic illnesses. These include CHF, COPD and Diabetes.

Concerning Toxicology Testing, AEON Global Health provides accurate and fast quantitative testing of drug metabolite levels in urine and oral fluids. The Company’s testing covers more than 80 analytes and metabolites. Its HPLC-tandem mass spectrometry can analyze wider molecular weight and polarity ranges of analytes, providing better selectivity and sensitivity.

AEON Clinical Labs services include Cancer Genomics, Pharmacogenomics, Toxicology, and Women’s Health. Health Technologies services include Inscrybe®. This is a secure and simple interface. Inscrybe® enables physicians, nurses, hospital staff, and external care facilities or health insurers to send, receive, sign, and track healthcare records, supporting documents, patient discharge orders and referrals or lab results and images on the web or via electronic fax instead of transferring paper.

In May 2018, AEON Global Health announced it earned The Joint Commission’s Gold Seal of Approval® for Laboratory Services Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal of Approval is a symbol of quality, which reflects an organization’s commitment to providing safe and effective patient care.

AEON Global Health underwent a thorough onsite survey earlier in 2018. During the review, a Joint Commission expert surveyor evaluated compliance with laboratory standards related to a number of areas. This included document and process control, healthcare-associated conditions, risk reduction, as well as staff qualifications and competency. Additionally, the surveyor conducted onsite observations and interviews.

AEON Global Health Corp. (AGHC), closed Friday's trading session at $0.284, up 56.9061%, on 513 volume with 4 trades. The average volume for the last 3 months is 2,067 and the stock's 52-week low/high is $0.155100002/$0.959999978.

chart

Vilacto Bio,  Inc. (VIBI)

OTC Markets and The Street reported on Vilacto Bio,  Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vilacto Bio,  Inc.  is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In numerous studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present the Company’s products are available on the market as Vilact®.

Founded in 2013, Vilacto Bio is headquartered in New York, New York. The Company previously went by the name Zlato, Inc. It changed its name to Vilacto Bio, Inc. on April 4, 2017. The Company’s European Headquarters are in Næstved, Denmark. Its Research and Development (R&D) operations are in Lithuania.

Vilacto Bio’s goal is to be the leading biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties.  The Company’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, as well as licensing out its Lactoactive® molecule for the pharmaceutical industry.

Lactoactive® is highly refined colostrum, developed to provide first-rate results for people needing healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin.  

Vilacto Bio has its Vilact Cuticle cream product, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with faster patient recovery.

This past January, Vilacto Bio announced that it started development of the Vilacto Bio Skincare Knowledge Center. This is an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.

The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines internationally, and also with Vilacto customers.  The expectation is that the Vilacto Bio Knowledge Center will enhance dialogue among specialists and consumers, improve outcomes, and drive higher traffic to Vilacto Bio’s commercial web portal.

Vilacto Bio,  Inc. (VIBI), closed Friday's trading session at $0.0003, up 50.00%, on 26,141,123 volume with 16 trades. The average volume for the last 3 months is 76,081,146 and the stock's 52-week low/high is $0.00019/$0.694000005.

chart

The QualityStocks Company Corner

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

Imaging3 (OTCQB: IGNG) today announced that its wholly owned subsidiary Grapefruit Boulevard Investments, Inc. has entered a letter of intent (‘LOI”) with Dogwood Management Group, Inc. Per the non-binding letter of intent dated June 12, 2019, the companies intend to have Grapefruit acquire and Dogwood manage licensed and fully compliant retail cannabis dispensaries throughout California that meet certain regulatory, operational and financial results requirements. To view the full press release, visit: http://cnw.fm/1lwUo.

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

  • Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
  • Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Friday's trading session at $0.09, up 6.0071%, on 79,111 volume with 11 trades. The average volume for the last 3 months is 198,996 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

chart

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio (NASDAQ: INMB) is an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, such as Alzheimer’s disease (“AD”). To view the full article, visit: http://nnw.fm/lmGO3.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed Friday's trading session at $9.35, up 1.5201%, on 8,132 volume with 50 trades. The average volume for the last 3 months is 13,417 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International Inc. (NASDAQ:YGYI) today announces its placement in an editorial published by CannabisNewsWire ("CNW"), a multifaceted financial news and publishing company for private and public entities in the cannabis industry. To view the full publication, titled, “Smart Companies Finding Sweet Spot in Cannabis Processing, Manufacturing Opportunities,” please visit: http://cnw.fm/OU0aI. Also today, the company announced entry of its wholly owned subsidiary, Khrysos Industries, into a one year supply and processing agreement to produce water soluble CBD Isolate, which contains no THC and is expected to generate revenues of $19 million. To view the full press release, visit: http://nnw.fm/EGff4.

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Friday's trading session at $5.08, up 1.8036%, on 196,264 volume with 1,329 trades. The average volume for the last 3 months is 101,046 and the stock's 52-week low/high is $3.56999993/$16.25.

Recent News

chart

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, announced today an additional sale of a prototype of its QuadSight™ four-camera vision system, targeted for the semi-autonomous and autonomous vehicle market. The prototype system was ordered by a leading Japanese Tier One automotive supplier. Revenue from the prototype system sale is expected to total tens of thousands of dollars.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed Friday's trading session at $1.81, up 4.023%, on 71,859 volume with 277 trades. The average volume for the last 3 months is 521,791 and the stock's 52-week low/high is $0.697000026/$3.17639994.

Recent News

chart

Willow Biosciences Inc. (CSE: WLLW)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (CSE: WLLW).

Canada-based Willow Biosciences (CSE: WLLW) was recently featured in a video by InvestmentPitch Media detailing how the company utilizes its proprietary biosynthetic processes to deliver high yields of ultra-pure, low-cost cannabinoids. To view the full article, visit: http://nnw.fm/0r7WM.

Willow Biosciences Inc. (CSE: WLLW) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (CSE: WLLW), closed Friday's trading session at $0.86, up 2.38%, on 19,631 volume. The average volume for the last 3 months is 60,400 and the stock's 52-week low/high is $0.76999998/$5.25.

Recent News

chart

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands (TSX.V: GYSR) announced key appointments to its leadership team recently, including the addition of Dr. Bin Huang to the company’s board of directors (http://nnw.fm/0VyV1). To view the full article, visit: http://nnw.fm/LCtS0.

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed Friday's trading session at $0.55, up 1.8519%, on 7,667 volume with 156,570 trades. The average volume for the last 3 months is 7,252 and the stock's 52-week low/high is $0.50999999/$0.850000023.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com Inc. (OTCQB: CIIX) is a foremost financial information website for Chinese-speaking investors in the United States, China, Canada and worldwide. The company has operated the premier web portal for more than 20 years. Through its website, CIIX provides real-time market commentary and analysis, as well as education-related services in both traditional and simplified Chinese language character sets (http://nnw.fm/2dWBs).

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Friday's trading session at $0.39, up 2.6316%, on 48,568 volume with 27 trades. The average volume for the last 3 months is 44,001 and the stock's 52-week low/high is $0.365000009/$1.25.

Recent News

chart

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an oil and gas industry technology innovator, on Thursday announced that its Form 10 Registrationda Statement filed with the U.S. Securities and Exchange Commission (“SEC”) became effective as of July 12, 2019.

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Friday's trading session at $0.19447, up 14.0587%, on 197,630 volume with 61 trades. The average volume for the last 3 months is 265,382 and the stock's 52-week low/high is $0.169740006/$1.42999994.

Recent News

chart

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF)

The QualityStocks Daily Newsletter would like to spotlight IONIC Brands Corp. (OTC: IONKF).

IONIC Brands (CSE: IONC) (OTC: IONKF) (FRA: IB3), a company with roots as a family-run business selling vape pens in Washington state, has transformed into an award-winning cannabis holding company with a multistate portfolio. To view the full article, visit: http://nnw.fm/8FdAV.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is a national cannabis holding company building a multistate portfolio of award-winning premium and luxury brands in the cannabis space. Established in 2015, IONIC Brands has demonstrated its ability to expand and operate multiple cannabis concentrate consumer brands in markets across the western United States. The company continues to strategically expand nationwide to remain a leader of the highest-value segments in the cannabis market.

With a focus on quality, responsibility and respectability, IONIC's product lines are pioneering the changing landscape of cannabis consumption. The company's refinement practices are a result of a passionate commitment to craft the finest, small-batch cannabis oils and cannabis concentrates in the world – without glycols, glycerins or additives.

IONIC's Certified Clean program verifies that every product leaving the company's facilities meets or exceeds state mandates on pesticide testing. The testing is conducted by individually testing every batch which ensures and enhances trust and transparency. IONIC recently paired its Certified Clean program with Lucid Green Inc. and its revolutionary technology platform designed to provide vital safety information. Lucid Green's technology provides a direct-to-consumer data platform, providing instant access to a library of product specific insights by simply scanning the package's QR code with a smartphone camera.

Elite Brand Portfolio/Acquisitions

  • IONIC, the company's flagship recreational branded product, is a stylish and sophisticated premium vape pen line that has earned customer loyalty and a reputation as a consistent Top 10 vape brand in Washington state. IONIC's immediate product line expansion plans include THC/CBD mixes, low-dose products, high-end edibles, CASK oil and device innovation.
  • WW Agriculture cultivates cannabis outdoors on a 140-acre eastern Washington State farm capable of producing up to 100,000 pounds of cannabis for less than $0.10/gram.
  • ZOOTS, a Washington-based edibles company, utilizes patent-protected ultra-clean CO2 extraction hardware to create proprietary formulations of refined cannabis oils and distillates. Through MedMen dispensaries, Zoots Edibles are currently available in Washington and Colorado and will soon be on shelves at dispensaries in Massachusetts, New York and Pennsylvania.
  • Vuber Technologies hardware produces the best vaporization experience on the market.
  • Vegas M Stick vaporizer pens are distributed to stores in Washington State with plans to expand to Oregon and Nevada.
  • Vegas Valley Growers is a revenue-generating, vertically integrated operation in Las Vegas, Nevada, with a full complement of production, manufacturing and distribution licenses.

IONIC has also acquired two U.S. patents issued to Canna Café that are related to cannabinoid (CBD) infused coffee and CBD-infused coffee in a Keurig ® K-Cup ® Pod. An international patent is in process for cannabis-infused teas.

Experienced Management Team

IONIC Brands is led by an innovative product team, powerful sales organization and a world-class marketing group.

Chairman & CEO John Gorst has built and sold four different technology companies with market valuations in excess of $600 million. Gorst has been at the forefront of IONIC's expansion and development into Washington state's leading vaporizer brand.

Andrew Schell, President, Vice-Chairman & Co-Founder, has built several successful companies. Schell has an engineering background rounded in operations, strategy and corporate law, and most recently was CEO of a U.S. Department of Defense company specializing in military operations.

Christian Struzan, Chief Marketing Officer & Co-Founder, has over 30 years of experience in marketing and branding in the entertainment and consumer goods industries. Struzan founded an advertising agency which developed and executed marketing campaigns for feature films such as the Star Wars franchise, Fight Club, and the television series American Idol. He has also worked on global brands such as Guinness, Stella Artois and Beck's.

Johnny Stange, Chief Revenue Officer, was formerly a director of sales for the southern California region for Treasury Wine Estates, a major wine wholesaler, where he grew and oversaw annual sales of $250 million. Stange is leading the charge in IONIC's aggressive sales growth plans across multiple states.

In 2018, IONIC was voted one of the "Top 50 Companies to Work for in Cannabis" by MG Magazine, a publication serving cannabis industry professionals.

IONIC Brands Corp. (OTC: IONKF), closed Friday's trading session at $0.1781, up 7.9394%, on 168,710 volume with 101 trades. The stock's 52-week low/high is $0.035999998/$0.634559988.

Recent News

chart

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ), a British Columbia-based company focused on the acquisition, exploration and development of natural resource properties, is ideally positioned as demand for lithium rapidly rises alongside the popularity of autonomous electric vehicles (“EVs”). According to a recent BloombergNEF report, the global demand for lithium is projected to reach one million tons per year by 2025 from the current 325,000 tons (http://nnw.fm/o1Fya). To view the full article, visit: http://nnw.fm/e71Kq.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed Friday's trading session at $0.1276, up 5.4545%, on 22,800 volume with 7 trades. The average volume for the last 3 months is 35,795 and the stock's 52-week low/high is $0.115500003/$0.319999992.

Recent News

chart

City View Green Holdings Inc. (CSE: CVGR)

The QualityStocks Daily Newsletter would like to spotlight City View Green Holdings Inc. (CVGR).

City View Green Holdings (CSE: CVGR), together with Budd Hutt, the company’s retail arm, recently announced an agreement to acquire eight retail cannabis store locations in Alberta. To view the full article, visit: http://nnw.fm/OGSh0.

City View Green Holdings Inc.'s (CSE: CVGR) (formerly Icon Exploration Inc.) primary objective is to create a well-diversified company focused on assessing and potentially acquiring targets in the cannabis industry. Icon Exploration recently signed a formal share exchange agreement relating to its proposed acquisition of privately held City View Green (“CVG”), a vertically integrated cannabis company incorporated under the laws of Ontario, Canada. CVG’s application to Health Canada for an A6ccess to Cannabis for Medical Purposes Regulations (“ACMPR”) license is now at the in-depth review stage of the licensing process.

CVG is preparing a 40,000-square-foot growing facility near Toronto to produce pharmaceutical-grade cannabis once its ACMPR license is granted. About half of the facility will initially be outfitted with state-of-the-art LED lighting, HVAC and dehumidification systems, and automation technologies to optimize the quality, safety and consistency of cannabis production. About 4,000 square feet will be devoted to an extraction laboratory featuring an ultra-efficient CO2 supercritical extraction process with plans to include ethanol extraction technology in the future.

Another 4.3 acres remains available for future construction of up to 125,000 square feet of grow and extraction space. Production plans include producing high quality edible products, distillates, and water-soluble products for the rapidly expanding CBD-infused (cannabidiol) beverage market.

Management

Icon and CVG have assembled a talented team that includes a Master Grower with cannabis-industry experience to manage indoor grow operations and an extraction expert whose expertise in developing and launching new products was honed while working in Washington state’s cannabis sector. Having gained experience in the Washington state market the extraction expert has a number of brand ideas and recreational cannabis products that became popular in the Washington market as well as a number of in-licensing branding opportunities available to CVG. CVG has also negotiated an agreement with a private company seeking 37 retail cannabis licenses in Alberta, Canada, that provides a reciprocal exchange of shares, product, shelf space and distribution lines. Early discussions with various entities in Europe to arrange an off-take agreement for CBD oils and extracts are also underway.

Market Opportunity

The Canadian medical cannabis market has steadily been growing with an average 10 percent increase in patients each month. Now that the Canadian federal government has legalized recreational cannabis for adult users nationwide, analysts project a compound annual growth rate of nearly 78 percent from 2018 to 2021, reaching an estimated $3 billion by 2021, ArcView Market Research reports. One study from Deloitte pegged the potential economic impact of legalized medical and recreational marijuana in Canada – including transportation, licensing fees and security – at more than $22 billion over the coming years. Health Canada’s most recent data show that sales of cannabis extracts grew 961 percent in the second quarter of 2017, compared to an 89 percent increase in growth of dried cannabis during the same period.

City View Green Holdings Inc. (CSE: CVGR), closed Friday's trading session at $0.13, even for the day, on 50,500 volume. The average volume for the last 3 months is 138,826 and the stock's 52-week low/high is $0.094999998/$0.465000003.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Canada’s only coast-to-coast premium cannabis producer, The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is passionate about its products. The company provides high-quality brands and products that elevate its mission of becoming a leader in the global cannabis industry. NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://nnw.fm/SPRWF.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Friday's trading session at $1.1061, off by 2.9737%, on 299,084 volume with 416 trades. The average volume for the last 3 months is 317,356 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) was featured today in the 420 with CNW by CannabisNewsWire. The recent wave of adult-use marijuana legalization across the U.S. has the potential of generating $22 billion in annual sales, but not everyone is thrilled about this development. New research that will soon be published in the Marketing Science journal shows that the alcohol industry is likely to take a hit once marijuana is legalized. The research was done by Pengyuan, an assistant professor at the Terry College of Business (University of Georgia). He worked with Guiyang Xiong from Syracuse University.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.78, off by 1.2658%, on 34,411 volume with 41 trades. The average volume for the last 3 months is 84,217 and the stock's 52-week low/high is $0.75/$2.24.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics Inc. (OTCQB: ENDV) is delivering a safe and reliable alternative to opioid medications for the management of pain. The global post-operative pain management market is anticipated to grow at a CAGR of 5.4 percent through 2023, with an increasing number of surgeries worldwide and a growing prevalence of different diseases as major factors for the growth of the market, according to a Market Research Future report (http://nnw.fm/TfD33). An increasing aging population around the globe will also has a considerable impact on the growth of the market, the report underlines.

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s?targeted?pulsed electromagnetic field?(tPEMF)?transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone.?

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy.?

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Endonovo Therapeutics Inc. (ENDV), closed Friday's trading session at $0.01208, off by 0.983607%, on 5,674,042 volume with 114 trades. The average volume for the last 3 months is 6,280,258 and the stock's 52-week low/high is $0.008999999/$0.066100001.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.